A Phase 3 trial of CCX168 in Complement 3 Glomerulopathy (C3G)

Trial Profile

A Phase 3 trial of CCX168 in Complement 3 Glomerulopathy (C3G)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Avacopan (Primary)
  • Indications Membranoproliferative glomerulonephritis
  • Focus Registrational; Therapeutic Use
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 07 Nov 2017 According to a ChemoCentryx media release, status changed from planning to recruiting.
    • 23 May 2017 According to a ChemoCentryx media release, the company is planning to initiate this trial in mid-2017.
    • 20 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top